Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Partner | Cancer Centers | <b>Mayo Clinic</b>

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Related Content:

Mayo ClinicOvarian Cancer
Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer
Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research
SHR-A1921 Demonstrates Early Efficacy in Platinum-Resistant Ovarian Cancer